3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
antineoplaston AS 2-1
3
antineoplaston A10
3
dactolisib
2
Temozolomide
2
Irinotecan
2
Everolimus
2
Bevacizumab
2
surufatinib
1
spartalizumab
1
poly ICLC
1
plerixafor
1
pasireotide
1
fosbretabulin
1
cixutumumab
1
adavosertib
1
Vaccines
1
TH 302
1
Sunitinib
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Radiation
1
PM 00104
1
Lapatinib
1
Immunologic Techniques
1
Immunoglobulin G
1
Genistein
1
Fentanyl
1
Donepezil
1
Disulfides
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neuroectodermal Tumors, Primitive
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts